{"id":141,"date":"2019-10-28T16:57:03","date_gmt":"2019-10-28T19:57:03","guid":{"rendered":"http:\/\/cmcphsolutions.com.host.valordigital.com.ar\/?p=1"},"modified":"2022-03-22T11:41:38","modified_gmt":"2022-03-22T11:41:38","slug":"hola-mundo","status":"publish","type":"post","link":"https:\/\/www.cmcphsolutions.com\/es\/hola-mundo\/","title":{"rendered":"La Comisi\u00f3n Europea aprueba Bavencio en combinaci\u00f3n con axitinib para el carcinoma de c\u00e9lulas renales avanzado"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>La aprobaci\u00f3n de la UE se basa en los resultados del ensayo JAVELIN Renal 101 que demuestran una mejora significativa en la supervivencia libre de progresi\u00f3n con avelumab en combinaci\u00f3n con axitinib, en comparaci\u00f3n con sunitinib.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Esta aprobaci\u00f3n se aplica a todos los grupos de riesgo del IMDC, e independientemente de la expresi\u00f3n PD-L1.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Merck y Pfizer han anunciado que la Comisi\u00f3n Europea (CE) ha aprobado Bavencio (avelumab) en combinaci\u00f3n con axitinib como tratamiento en primera l\u00ednea de pacientes adultos con carcinoma de c\u00e9lulas renales avanzado (CCR). La aprobaci\u00f3n se basa en los resultados positivos del an\u00e1lisis intermedio del estudio Fase III JAVELIN Renal 101, que demuestra que avelumab en combinaci\u00f3n con axitinib reduce significativamente el riesgo de progresi\u00f3n de la enfermedad o muerte en un 31% (HR: 0,69 [IC del 95%: 0,574-0,825; p&lt;0,0001]), y casi duplica la tasa de respuesta objetiva (ORR; 52,5%[IC del 95%: 47,7-57,2] vs. 27,3% [IC del 95%: 23,2-31,6]) en comparaci\u00f3n con sunitinib en pacientes con CCR avanzado, independientemente de la expresi\u00f3n PD-L1.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El estudio incluy\u00f3 pacientes de todos los grupos de riesgo de la base de datos del Consorcio Internacional de CCR metast\u00e1sico (IMDC, por sus siglas en ingl\u00e9s). Observ\u00e1ndose mejor\u00eda en la supervivencia libre de progresi\u00f3n (SLP) entre los subgrupos preespecificados en los pacientes que recibieron el tratamiento en combinaci\u00f3n. Merck y Pfizer tienen una alianza estrat\u00e9gica global para desarrollar y comercializar conjuntamente avelumab.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201c<em>Existe una alta incidencia de c\u00e1ncer de ri\u00f1\u00f3n en Europa, y para el carcinoma de c\u00e9lulas renales, que es el tipo m\u00e1s com\u00fan, se contin\u00faan necesitando opciones de tratamiento adicionales, en particular, para los pacientes con enfermedad avanzada donde los resultados son m\u00e1s pobres<\/em>\u201d, ha subrayado el profesor James Larkin, consultor m\u00e9dico onc\u00f3logo en la Royal Marsden NHS Foundation Trust y profesor del Instituto de Investigaci\u00f3n del C\u00e1ncer (ICR, por sus siglas en ingl\u00e9s). \u201c<em>Hemos observado un beneficio demostrado en la eficacia y un perfil de seguridad y tolerabilidad de avelumab en combinaci\u00f3n con axitinib en todos los grupos de riesgo en pacientes con carcinoma de c\u00e9lulas renales avanzado, por lo que esta aprobaci\u00f3n en Europa ofrece una importante opci\u00f3n que puede ayudar a los profesionales sanitarios a optimizar las estrategias de tratamiento a trav\u00e9s de todos los grupos de riesgo<\/em>\u201d, ha a\u00f1adido.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En 2019 se estima que se diagnosticaron 7.331 nuevos casos de c\u00e1ncer de ri\u00f1\u00f3n en Espa\u00f1a. Muchos pacientes que viven con CCR avanzado no reciben tratamiento adicional despu\u00e9s de la terapia de primera l\u00ednea por razones que incluyen un mal estatus basal o eventos adversos derivados de su tratamiento inicial. La tasa de supervivencia a cinco a\u00f1os para pacientes con CCR avanzado es de aproximadamente el 12%.&nbsp;<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201c<em>Esta primera aprobaci\u00f3n europea de un anti-PD-L1 como parte de un tratamiento combinado para el carcinoma de c\u00e9lulas renales avanzado se basa en nuestro compromiso de ofrecer opciones de tratamiento innovadoras a los pacientes con c\u00e1nceres dif\u00edciles de tratar a trav\u00e9s de nuestro amplio programa de ensayos cl\u00ednicos JAVELIN<\/em>\u201d, ha explicado Rehan Verjee, director global de la Franquicia de Medicina Innovadora para el \u00e1rea de Biofarma de Merck. \u201c<em>El CCR es el tipo m\u00e1s com\u00fan de c\u00e1ncer de ri\u00f1\u00f3n y representa el 90% de los diagn\u00f3sticos. Ahora estamos trabajando para que avelumab en combinaci\u00f3n con axitinib est\u00e9 disponible lo antes posible para pacientes con carcinoma de c\u00e9lulas renales avanzado<\/em>\u201d, ha concluido.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201c<em>La aprobaci\u00f3n por parte de la Comisi\u00f3n Europea de avelumab en combinaci\u00f3n con axitinib tiene el potencial de ofrecer a todav\u00eda m\u00e1s pacientes con carcinoma de c\u00e9lulas renales avanzado un nuevo tratamiento en primera l\u00ednea, y nos permite continuar cumpliendo con nuestro compromiso, de m\u00e1s de una d\u00e9cada, de poner los m\u00e1ximos esfuerzos posibles por los pacientes con c\u00e1ncer de ri\u00f1\u00f3n<\/em>\u201d, ha destacado Andy Schmeltz, presidente global del \u00e1rea de Oncolog\u00eda de Pfizer. \u201c<em>Agradecemos a todos los investigadores, m\u00e9dicos, pacientes y sus familias que nos han ayudado a llegar hasta aqu\u00ed hoy, y continuaremos con nuestra lucha contra este c\u00e1ncer avanzado<\/em>\u201d.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La decisi\u00f3n de la CE llega despu\u00e9s de la aprobaci\u00f3n por parte de la Agencia Americana del Medicamento (FDA) de avelumab en combinaci\u00f3n con axitinib para el tratamiento en primera l\u00ednea de pacientes con CCR avanzado en mayo de 2019. En enero del mismo a\u00f1o se present\u00f3 en Jap\u00f3n una solicitud complementaria para avelumab en combinaci\u00f3n con axitinib en CCR metast\u00e1sico o irresecable.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Adem\u00e1s, mediante esta aprobaci\u00f3n, se ha actualizado la secci\u00f3n de posolog\u00eda en la ficha t\u00e9cnica de avelumab. La dosis recomendada como monoterapia es de 800 mg administrados por v\u00eda intravenosa durante 60 minutos cada 2 semanas. La administraci\u00f3n de avelumab debe continuar seg\u00fan el calendario recomendado hasta que la enfermedad progrese o hasta que la toxicidad sea inaceptable. La dosis recomendada de avelumab en combinaci\u00f3n con axitinib es de 800 mg administrados por v\u00eda intravenosa durante 60 minutos cada 2 semanas y 5 mg de axitinib tomados por v\u00eda oral dos veces al d\u00eda (con 12 horas de diferencia) con o sin alimentos hasta que la enfermedad progrese o hasta que la toxicidad sea inaceptable.&nbsp;<br>M\u00e1s sobre MERCK:<a rel=\"noreferrer noopener\" href=\"http:\/\/www.merck.es\/\" target=\"_blank\">http:\/\/www.merck.es<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Fuente: pmfarma.es<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La aprobaci\u00f3n de la UE se basa en los resultados del ensayo JAVELIN Renal 101 que demuestran una mejora significativa en la supervivencia libre de progresi\u00f3n con avelumab en combinaci\u00f3n con axitinib, en comparaci\u00f3n con sunitinib. Esta aprobaci\u00f3n se aplica a todos los grupos de riesgo del IMDC, e independientemente de la expresi\u00f3n PD-L1. Merck [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":733,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[6],"tags":[],"class_list":["post-141","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cmc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma | CMC Pharma Solutions<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cmcphsolutions.com\/es\/hola-mundo\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma | CMC Pharma Solutions\" \/>\n<meta property=\"og:description\" content=\"La aprobaci\u00f3n de la UE se basa en los resultados del ensayo JAVELIN Renal 101 que demuestran una mejora significativa en la supervivencia libre de progresi\u00f3n con avelumab en combinaci\u00f3n con axitinib, en comparaci\u00f3n con sunitinib. Esta aprobaci\u00f3n se aplica a todos los grupos de riesgo del IMDC, e independientemente de la expresi\u00f3n PD-L1. Merck [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cmcphsolutions.com\/es\/hola-mundo\/\" \/>\n<meta property=\"og:site_name\" content=\"CMC Pharma Solutions\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-28T19:57:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-03-22T11:41:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cmcphsolutions.com\/wp-content\/uploads\/2019\/10\/ImageForArticle_180291-e1572971416226.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"581\" \/>\n\t<meta property=\"og:image:height\" content=\"378\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"cmcphsolcmc\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"cmcphsolcmc\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/\"},\"author\":{\"name\":\"cmcphsolcmc\",\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/#\\\/schema\\\/person\\\/af0cb75dac70afd9614d4bd633d775fe\"},\"headline\":\"The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma\",\"datePublished\":\"2019-10-28T19:57:03+00:00\",\"dateModified\":\"2022-03-22T11:41:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/\"},\"wordCount\":933,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/ImageForArticle_180291-e1572971416226.jpg\",\"articleSection\":[\"CMC\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/\",\"url\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/\",\"name\":\"The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma | CMC Pharma Solutions\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/ImageForArticle_180291-e1572971416226.jpg\",\"datePublished\":\"2019-10-28T19:57:03+00:00\",\"dateModified\":\"2022-03-22T11:41:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/ImageForArticle_180291-e1572971416226.jpg\",\"contentUrl\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/wp-content\\\/uploads\\\/2019\\\/10\\\/ImageForArticle_180291-e1572971416226.jpg\",\"width\":581,\"height\":378},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/hola-mundo\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/#website\",\"url\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/\",\"name\":\"CMC Pharma Solutions\",\"description\":\"Distributes the CRONO series of Can\u00e8 Medical Technology in Latin America\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/#organization\"},\"alternateName\":\"CMC\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/#organization\",\"name\":\"CMC Pharma Solutions\",\"url\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/cmc_favicon.png\",\"contentUrl\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/cmc_favicon.png\",\"width\":300,\"height\":300,\"caption\":\"CMC Pharma Solutions\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/cmcphsolutions\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/#\\\/schema\\\/person\\\/af0cb75dac70afd9614d4bd633d775fe\",\"name\":\"cmcphsolcmc\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0f8f12dc18bd4692b2b16d0e8e56ddf762314f035625dff0326c570a56bd7082?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0f8f12dc18bd4692b2b16d0e8e56ddf762314f035625dff0326c570a56bd7082?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0f8f12dc18bd4692b2b16d0e8e56ddf762314f035625dff0326c570a56bd7082?s=96&d=mm&r=g\",\"caption\":\"cmcphsolcmc\"},\"sameAs\":[\"https:\\\/\\\/cmcphsol-cp5007.wordpresstemporal.com\\\/nueva\"],\"url\":\"https:\\\/\\\/www.cmcphsolutions.com\\\/es\\\/author\\\/cmcphsolcmc\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma | CMC Pharma Solutions","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cmcphsolutions.com\/es\/hola-mundo\/","og_locale":"es_ES","og_type":"article","og_title":"The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma | CMC Pharma Solutions","og_description":"La aprobaci\u00f3n de la UE se basa en los resultados del ensayo JAVELIN Renal 101 que demuestran una mejora significativa en la supervivencia libre de progresi\u00f3n con avelumab en combinaci\u00f3n con axitinib, en comparaci\u00f3n con sunitinib. Esta aprobaci\u00f3n se aplica a todos los grupos de riesgo del IMDC, e independientemente de la expresi\u00f3n PD-L1. Merck [&hellip;]","og_url":"https:\/\/www.cmcphsolutions.com\/es\/hola-mundo\/","og_site_name":"CMC Pharma Solutions","article_published_time":"2019-10-28T19:57:03+00:00","article_modified_time":"2022-03-22T11:41:38+00:00","og_image":[{"width":581,"height":378,"url":"https:\/\/www.cmcphsolutions.com\/wp-content\/uploads\/2019\/10\/ImageForArticle_180291-e1572971416226.jpg","type":"image\/jpeg"}],"author":"cmcphsolcmc","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"cmcphsolcmc","Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/#article","isPartOf":{"@id":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/"},"author":{"name":"cmcphsolcmc","@id":"https:\/\/www.cmcphsolutions.com\/#\/schema\/person\/af0cb75dac70afd9614d4bd633d775fe"},"headline":"The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma","datePublished":"2019-10-28T19:57:03+00:00","dateModified":"2022-03-22T11:41:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/"},"wordCount":933,"commentCount":0,"publisher":{"@id":"https:\/\/www.cmcphsolutions.com\/#organization"},"image":{"@id":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cmcphsolutions.com\/wp-content\/uploads\/2019\/10\/ImageForArticle_180291-e1572971416226.jpg","articleSection":["CMC"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/","url":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/","name":"The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma | CMC Pharma Solutions","isPartOf":{"@id":"https:\/\/www.cmcphsolutions.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/#primaryimage"},"image":{"@id":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cmcphsolutions.com\/wp-content\/uploads\/2019\/10\/ImageForArticle_180291-e1572971416226.jpg","datePublished":"2019-10-28T19:57:03+00:00","dateModified":"2022-03-22T11:41:38+00:00","breadcrumb":{"@id":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cmcphsolutions.com\/hola-mundo\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/#primaryimage","url":"https:\/\/www.cmcphsolutions.com\/wp-content\/uploads\/2019\/10\/ImageForArticle_180291-e1572971416226.jpg","contentUrl":"https:\/\/www.cmcphsolutions.com\/wp-content\/uploads\/2019\/10\/ImageForArticle_180291-e1572971416226.jpg","width":581,"height":378},{"@type":"BreadcrumbList","@id":"https:\/\/www.cmcphsolutions.com\/hola-mundo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cmcphsolutions.com\/"},{"@type":"ListItem","position":2,"name":"The European Commission approves Bavencio in combination with axitinib for advanced renal cell carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/www.cmcphsolutions.com\/#website","url":"https:\/\/www.cmcphsolutions.com\/","name":"CMC Pharma Solutions","description":"Distributes the CRONO series of Can\u00e8 Medical Technology in Latin America","publisher":{"@id":"https:\/\/www.cmcphsolutions.com\/#organization"},"alternateName":"CMC","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cmcphsolutions.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cmcphsolutions.com\/#organization","name":"CMC Pharma Solutions","url":"https:\/\/www.cmcphsolutions.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cmcphsolutions.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.cmcphsolutions.com\/wp-content\/uploads\/2022\/03\/cmc_favicon.png","contentUrl":"https:\/\/www.cmcphsolutions.com\/wp-content\/uploads\/2022\/03\/cmc_favicon.png","width":300,"height":300,"caption":"CMC Pharma Solutions"},"image":{"@id":"https:\/\/www.cmcphsolutions.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/cmcphsolutions\/"]},{"@type":"Person","@id":"https:\/\/www.cmcphsolutions.com\/#\/schema\/person\/af0cb75dac70afd9614d4bd633d775fe","name":"cmcphsolcmc","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/0f8f12dc18bd4692b2b16d0e8e56ddf762314f035625dff0326c570a56bd7082?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0f8f12dc18bd4692b2b16d0e8e56ddf762314f035625dff0326c570a56bd7082?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0f8f12dc18bd4692b2b16d0e8e56ddf762314f035625dff0326c570a56bd7082?s=96&d=mm&r=g","caption":"cmcphsolcmc"},"sameAs":["https:\/\/cmcphsol-cp5007.wordpresstemporal.com\/nueva"],"url":"https:\/\/www.cmcphsolutions.com\/es\/author\/cmcphsolcmc\/"}]}},"_links":{"self":[{"href":"https:\/\/www.cmcphsolutions.com\/es\/wp-json\/wp\/v2\/posts\/141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cmcphsolutions.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cmcphsolutions.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cmcphsolutions.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cmcphsolutions.com\/es\/wp-json\/wp\/v2\/comments?post=141"}],"version-history":[{"count":0,"href":"https:\/\/www.cmcphsolutions.com\/es\/wp-json\/wp\/v2\/posts\/141\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cmcphsolutions.com\/es\/wp-json\/wp\/v2\/media\/733"}],"wp:attachment":[{"href":"https:\/\/www.cmcphsolutions.com\/es\/wp-json\/wp\/v2\/media?parent=141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cmcphsolutions.com\/es\/wp-json\/wp\/v2\/categories?post=141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cmcphsolutions.com\/es\/wp-json\/wp\/v2\/tags?post=141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}